Skip to main content
. 2021 Apr 12;12:20406207211006022. doi: 10.1177/20406207211006022

Table 1.

Comparison of IV iron formulations.

IV iron product Brand name Standard label maximum single dose Infusion time Recommended doses Risk and incidence of HSRs Average wholesale price9 Miscellaneous
Low molecular weight iron dextran Cosmofer® INFeD® 1000 mg 4–6 h; 1-h infusion has also been described10 Multiple doses of 100 mg or single dose of 1000 mg Highest risk11 $0.35/mg Test dose required with 1-h observation period
Any HSR: 4.7–5.6%12,13
Mod to severe HSR: 0.7%4
Ferric gluconate Ferrlecit® 125 mg 60 min Multiple doses Low risk $1.64/mg
Any HSR: 3.9%14
Mod to severe HSR: 0.4%14
Iron sucrose Venofer® 500 mg 3.5–5 h Multiple doses Low risk $0.60/mg
Any HSR: 5.0%15
Mod to severe HSRs: 0.4%16
Ferumoxytol Feraheme ® Rienso® 510 mg 15 min Two doses given 3–8 days apart Low risk $2.50/mg MRI scans may appear contrast enhanced for up to 3 months following use18
Any HSR: 2.7%15
Mod to severe HSRs: 0.6%17
Ferric carboxymaltose (FCM) Ferinject® Injectafer® 750 mg for patients over 50 kg; 15 mg/kg for patients <50 kg 15 min Two doses given 7 or more days apart Low risk $1.82/mg Hypophosphatemia is seen in 50% of patients and can persist five weeks or more20
Any HSR: 2.1%17,19
Mod to severe HSRs: 0.7%
Ferric derisomaltose (formerly iron isomaltoside) Monofer® Monoferric® 20 mg/kg, not to exceed 1500 mg 15–30 min Single dose Low to intermediate risk Not available Associated with fetal bradycardia following maternal administration21
Any HSR: 8.7%
Mod to severe HSRs: 0.3–66.4%16,19

HSR, hypersensitivity reaction; IV, intravenous.